DONG Energy is an offshore wind power provider for both the industrial and commercial market. They are committed to driving down the costs of wind power and developing innovative solutions to reuse energy. The Danish company is now teaming up with biogas provider, Bigadan to build a large-scale biogas plant to produce green energy from biogas. This new biogas plant in Kalundborg will convert residues from the factories of Novozymes and Novo Nordisk to bio natural gas which can be fed directly into the Danish natural gas grid. The collaboration will begin official operations in Spring 2018.
"The biogas plant will have a production capacity of eight million m3 of natural gas per year. This corresponds to the natural gas consumption of approximately 5,000 households."
In Kalundborg, Novo Nordisk and Novozymes have a large-scale production of enzymes and insulins, among other things, that are sold all over the world. Now, biomass from this facility will be converted into energy in a local plant.
DONG Energy believe that this is great example of how residues can be utilised even better. The biogas will be a good supplement to the green power from wind and solar power and the green district heating from power stations. “This project is therefore an important step in the direction of a green, independent and economically sustainable energy system," says Thomas Dalsgaard, Executive Vice President in DONG Energy.
Construction of the new biogas plant will commenced last month, and the plant is scheduled for commissioning already in the spring of 2018. The biogas plant will have a production capacity of eight million m3 of natural gas per year. This corresponds to the natural gas consumption of approximately 5,000 households.
Bigadan and DONG Energy will build and own the biogas plant which will be located close to DONG Energy's power station in Kalundborg. Bigadan, which has more than 30 years of experience in the biogas industry, will operate the plant, and Novo Nordisk and Novozymes will supply biomass from their factories in Kalundborg and Novozymes' factory at Fuglebakken in Copenhagen.
"Novo Nordisk is very pleased with the partnership and is looking forward to the cooperation. During 2018, we'll be able to better utilise our biomass for biogas production while also significantly shortening the transport distance between our factories and the recipient of our biomass. All in all, it's a great optimisation for our production," says Michael Hallgren, Head of Production, Novo Nordisk Kalundborg.
The production of enzymes and insulin is based on fermentation processes and can be compared with beer brewing. This opens up the possibility of reusing the residual biomass. With the new biogas plant, the residues will first be converted into biogas which will then be upgraded to bio natural gas. And when the biomass has been processed at the biogas plant, it will continue to be used as fertiliser in the fields, just like it has been for several years already.
"This agreement is a double-up in terms of reusing Novozymes' residues, and both the environment and Novozymes are gaining from it. It's important to Novozymes to reduce the environmental impact from our production. For several years, we've invested heavily in reducing energy consumption by reusing our resources. We've succeeded in this and now we're taking the next step," says Jesper Haugaard, Head of Novozymes' production in Europe.
For more related content you might be interested in: